Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
    5.
    发明授权
    Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide 失效
    (R)-N- [5-甲基-8-(4-甲基哌嗪-1-基)-1,2,3,4-四氢-2-萘基] -4-吗啉代苯甲酰胺

    公开(公告)号:US06706710B2

    公开(公告)日:2004-03-16

    申请号:US10333286

    申请日:2003-01-17

    IPC分类号: A61K315327

    CPC分类号: C07D295/135

    摘要: This invention relates to a novel form of a scrotonin h5-HT1B-receptor antagonist, namely a novel form of a salt of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,2,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide referred to as (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphtyl]-4-morpholinobenzamide monohydrobromide Form A. The invention also relates to processes for preparation of said of Form A, which form has a potential use after suitable pharmaceutical formulation in medical treatment, preferably in CNS disorders, over active bladder or vasospam, or growth control of tumors.

    摘要翻译: 本发明涉及一种新型形式的角质蛋白h5-HT1B受体拮抗剂,即(R)-N- [5-甲基-8-(4-甲基哌嗪-1-基) 称为(R)-N- [5-甲基-8-(4-甲基哌嗪-1-基)-1,2,3,4-四氢-2-萘基] -4-吗啉代苯甲酰胺, 四氢-2-萘基] -4-吗啉代苯甲酰胺单氢溴酸盐形式A.本发明还涉及制备所述形式A的方法,该形式在药物治疗中优选在CNS障碍中的适当药物制剂之后具有潜在用途,超过活性膀胱 或血管紧张素,或肿瘤的生长控制。

    New Process 298
    6.
    发明申请
    New Process 298 审中-公开
    新进程298

    公开(公告)号:US20080139846A1

    公开(公告)日:2008-06-12

    申请号:US11846135

    申请日:2007-08-28

    IPC分类号: C07C233/57 C07C209/00

    摘要: A process for preparing a compound of formula I wherein R1 is H, C1-6alkyl, C2-6alkenyl, C1-6alkoxy, —OH, or amino; and n, m, and p are independently selected from 0, 1 and 2; which process comprises reacting a compound of formula II, by combining it with a reducing agent in a suitable solvent into a reaction mixture.

    摘要翻译: 一种制备式I化合物的方法,其中R 1是H,C 1-6烷基,C 2-6链烯基,C 1 -C 6烷基, 烷氧基,-OH或氨基; 并且n,m和p独立地选自0,1和2; 该方法包括通过将式II化合物与还原剂在合适的溶剂中合并成反应混合物来进行反应。